AR052283A1 - Conjugados de un polipeptido y un pentasacarido que tienen propiedades farmacocineticas mejoradas y su uso en la fabricacion de medicamentos - Google Patents

Conjugados de un polipeptido y un pentasacarido que tienen propiedades farmacocineticas mejoradas y su uso en la fabricacion de medicamentos

Info

Publication number
AR052283A1
AR052283A1 ARP060100324A ARP060100324A AR052283A1 AR 052283 A1 AR052283 A1 AR 052283A1 AR P060100324 A ARP060100324 A AR P060100324A AR P060100324 A ARP060100324 A AR P060100324A AR 052283 A1 AR052283 A1 AR 052283A1
Authority
AR
Argentina
Prior art keywords
polypeptide
conjugates
oligosaccharide
properties
improved
Prior art date
Application number
ARP060100324A
Other languages
English (en)
Inventor
E S Bos
Kort M De
M J Smit
Boeckel C A A Van
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of AR052283A1 publication Critical patent/AR052283A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente se refiere a conjugado de un polipéptido y un oligosacárido, donde el polipéptido está conjugado con al menos un residuo de oligosacárido-espaciador, donde el oligasacárido es un oligosacárido sulfatado sintético que comprende 4-16 unidades de monosacáridos y tiene afinidad per se por antitrombina III, y el espaciador es un enlace o un residuo enlazador flexible que esencialmente es farmacologicamente inactivo, o una sal farmacéuticamente aceptable del mismo. Los conjugados de la presente tienen propiedades farmacocinéticas mejoradas cuando se comparan con los polipéptidos originales (o sea, los polipéptidos no conjugados correspondientes per se).
ARP060100324A 2005-02-01 2006-01-30 Conjugados de un polipeptido y un pentasacarido que tienen propiedades farmacocineticas mejoradas y su uso en la fabricacion de medicamentos AR052283A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05100688 2005-02-01

Publications (1)

Publication Number Publication Date
AR052283A1 true AR052283A1 (es) 2007-03-07

Family

ID=35532856

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100324A AR052283A1 (es) 2005-02-01 2006-01-30 Conjugados de un polipeptido y un pentasacarido que tienen propiedades farmacocineticas mejoradas y su uso en la fabricacion de medicamentos

Country Status (20)

Country Link
US (2) US8106007B2 (es)
EP (1) EP1976563A2 (es)
JP (1) JP5134374B2 (es)
KR (1) KR20070108535A (es)
CN (1) CN101111268A (es)
AR (1) AR052283A1 (es)
AU (1) AU2006210230B2 (es)
BR (1) BRPI0607248A2 (es)
CA (1) CA2594970A1 (es)
IL (1) IL184565A0 (es)
MX (1) MX2007009243A (es)
MY (1) MY148776A (es)
NO (1) NO20073756L (es)
NZ (1) NZ556581A (es)
PE (1) PE20060880A1 (es)
RU (1) RU2443713C2 (es)
TW (1) TWI376234B (es)
UA (1) UA96916C2 (es)
WO (1) WO2006082184A2 (es)
ZA (1) ZA200705904B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101400105B1 (ko) 2006-07-25 2014-06-19 리폭센 테크놀로지즈 리미티드 Ｎ-말단 폴리시알화
EP1886696A1 (en) * 2006-08-03 2008-02-13 Endotis Pharma Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins
RU2543157C2 (ru) * 2008-06-17 2015-02-27 Глитек,Инк. Гликозилированный пептид glp-1
JP2011530507A (ja) 2008-08-07 2011-12-22 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ グルコース依存性インスリン分泌刺激ポリペプチドアナログ
EP2987805A3 (en) * 2008-08-07 2016-04-13 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
WO2010033224A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of kiss1 peptides
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
AU2010208381A1 (en) 2009-01-28 2011-08-04 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
PE20120582A1 (es) 2009-01-28 2012-05-26 Smartcells Inc Conjugados de insulina cristalina
CA2750252A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
SG173112A1 (en) 2009-01-28 2011-08-29 Smartcells Inc Conjugate based systems for controlled drug delivery
AU2010226243A1 (en) 2009-03-20 2011-09-22 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
US8569231B2 (en) 2009-03-20 2013-10-29 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
EP2598170A4 (en) 2010-07-28 2016-07-06 Smartcells Inc MEDICAMENT-LIGAND CONJUGATES, THEIR SYNTHESIS AND CORRESPONDING INTERMEDIATES
AU2011282988A1 (en) 2010-07-28 2013-01-31 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
JP2013541500A (ja) 2010-07-28 2013-11-14 スマートセルズ・インコーポレイテツド 組換えレクチン、結合部位修飾レクチンおよびそれらの用途
RU2452509C1 (ru) * 2011-01-31 2012-06-10 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" ООО "Саентифик Фьючер Менеджмент" Средство для стимуляции роста организма
US9694051B2 (en) 2011-04-07 2017-07-04 The Board Of Trustees Of The Leland Stanford Junior University Long-acting peptide analogs
WO2013017631A1 (en) 2011-08-04 2013-02-07 Msd Oss B.V. Kisspeptide-pentasaccharide conjugates
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
US9700599B2 (en) 2012-11-13 2017-07-11 Adocia Rapid-acting insulin formulation comprising a substituted anionic compound
CA2890048C (en) 2012-12-03 2022-05-03 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
BR112016007176A2 (pt) 2013-10-04 2018-01-23 Merck Sharp & Dohme conjugado, composição, usos de um conjugado e de uma composição, e, método para tratar um indivíduo que tem diabete
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
SG10202107752PA (en) * 2014-03-31 2021-09-29 Hanmi Pharmaceutical Co Ltd Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
AU2016249391A1 (en) * 2015-04-15 2017-12-07 Attwill Medical Solutions Inc. Antithrombin-heparin compositions and methods
JP2018524067A (ja) 2015-06-11 2018-08-30 アットウィル メディカル ソルーションズ インコーポレイテッド アンチトロンビン−ヘパリン組成物を利用する医療機器、システムおよび方法
AU2016324119B2 (en) * 2015-09-18 2019-11-14 Himuka AM Australia Pty Ltd. Long-acting adrenomedullin derivative
US11034745B2 (en) 2016-01-04 2021-06-15 Adepthera Llc Superagonist polypeptide analogs of adrenomedullin and intermedin peptide hormones
CN109475604B (zh) 2016-02-09 2023-04-04 艾得佩索拉公司 长效型clr/ramp激动剂的配量和用途
RU2656140C2 (ru) * 2016-11-14 2018-05-31 Федеральное государственное бюджетное учреждение "Государственный научный центр Институт иммунологии" Федерального медико-биологического агентства России Способ получения гибридного белка, состоящего из рекомбинантного белка аналога интерферона гамма, конъюгированного с олигосахаридом
CN107320718B (zh) * 2017-05-23 2020-12-11 余红 促生长激素释放激素激动剂在制备抗血管钙化药物中的应用
AU2018300069A1 (en) 2017-07-11 2020-02-27 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
US20200181220A1 (en) 2017-08-03 2020-06-11 Synthorx, Inc. Cytokine conjugates for the treatment of proliferative and infectious diseases
EP3727424A4 (en) * 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN RELEASE
CN114949240A (zh) 2019-02-06 2022-08-30 新索思股份有限公司 Il-2缀合物及其使用方法
WO2020203626A1 (ja) 2019-03-29 2020-10-08 日油株式会社 分岐型分解性ポリエチレングリコール結合体
EP3950776A4 (en) 2019-03-29 2023-01-04 NOF Corporation BRANCHED AND DEGRADABLE POLYETHYLENE GLYCOL DERIVATIVE
WO2023288336A1 (en) * 2021-07-16 2023-01-19 Washington University Methods of detecting pentasaccharides and treatment and monitoring of lysosomal storage disease
CN114869879A (zh) * 2022-05-09 2022-08-09 南方医科大学珠江医院 一种具备活性氧和炎症双重抑制作用的小分子水凝胶及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4652525A (en) * 1978-04-19 1987-03-24 The Regents Of The University Of California Recombinant bacterial plasmids containing the coding sequences of insulin genes
US4431740A (en) * 1979-09-12 1984-02-14 The Regents Of The University Of California DNA Transfer vector and transformed microorganism containing human proinsulin and pre-proinsulin genes
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
DE3844211A1 (de) * 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
JPH02231077A (ja) 1989-03-03 1990-09-13 Ube Ind Ltd ヘパリン修飾スーパーオキシドジスムターゼ
DE69100275T2 (de) 1990-04-23 1993-12-02 Akzo Nv Eine Trisaccharideinheit enthaltende Kohlenhydratderivate.
GB9112212D0 (en) 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
US5268453A (en) * 1991-08-08 1993-12-07 Scios Inc. Tissue-selective insulin analogs
IL102758A (en) 1991-08-23 1997-03-18 Akzo Nv Glycosaminoglycanoid derivatives, their preparation and pharmaceutical compositions comprising them
EP0938502B1 (en) 1996-07-11 2004-10-06 Novo Nordisk A/S Selective acylation method
FR2751334B1 (fr) 1996-07-19 1998-10-16 Sanofi Sa Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant
BRPI9711437B8 (pt) * 1996-08-30 2021-05-25 Novo Nordisk As derivados de glp-1
JPH1121250A (ja) * 1997-07-02 1999-01-26 Kyowa Hakko Kogyo Co Ltd 医薬製剤
FR2773801B1 (fr) * 1998-01-19 2000-05-12 Sanofi Sa Nouveaux pentasaccharides, procedes pour leurs preparations et compositions pharmaceutiques les contenant
CA2321026A1 (en) * 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6486129B1 (en) * 1998-06-17 2002-11-26 Akzo Nobel N.V. Antithrombotic compounds
AR020848A1 (es) 1998-10-23 2002-05-29 Amgen Inc Metodos y composiciones para la prevencion y el tratamiento de anemia
AU2602200A (en) 1999-01-08 2000-07-24 Board Of Trustees Of The University Of Arkansas, The Synthetic, highly charged molecules and uses thereof
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6329336B1 (en) 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
TWI289566B (en) 1999-12-07 2007-11-11 N.V.Organon Antithrombotic compound
WO2001087922A2 (en) 2000-05-16 2001-11-22 Lipoxen Technologies Limited Derivatisation of proteins in aqueous solution
FR2814463B1 (fr) * 2000-09-22 2002-11-15 Sanofi Synthelabo Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine
BR0209896A (pt) * 2001-05-21 2004-08-17 Nektar Therapeutics Composição de insulina para administração pulmonar, e, métodos para suprir insulina a um indivìduo mamìfero, para prover uma composição de insulina não-imunogênica e uma composição de insulina de efeito prolongado para administração ao pulmão de um indivìduo
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
JP2004537580A (ja) 2001-08-10 2004-12-16 エピックス メディカル， インコーポレイテッド 延長された循環半減期を有するポリペプチド結合体
AU2003273297A1 (en) 2002-09-09 2004-03-29 Kenneth S. Warren Institute, Inc. Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
AU2003273413A1 (en) 2002-10-08 2004-05-04 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
WO2004060404A1 (ja) * 2002-12-27 2004-07-22 Chugai Seiyaku Kabushiki Kaisha 薬物担体
PL1605897T3 (pl) 2003-03-19 2012-12-31 Lilly Co Eli Związki będące połączeniem GLP-1 z poli(glikolem etylenowym)
US9040664B2 (en) 2003-04-11 2015-05-26 Antriabio, Inc. Materials and methods for preparing protein-polymer conjugates
ES2328579T3 (es) 2003-07-25 2009-11-16 Conjuchem Biotechnologies Inc. Derivados de insulina de larga duracion y procedimientos asociados.
RU2006120079A (ru) 2003-12-18 2008-01-27 Ново Нордиск А/С (DK) Производные глюкагоноподобного пептида-1 (glp-1)

Also Published As

Publication number Publication date
US20120039843A1 (en) 2012-02-16
JP2008538200A (ja) 2008-10-16
WO2006082184A3 (en) 2007-06-07
NZ556581A (en) 2011-06-30
ZA200705904B (en) 2008-07-30
US8106007B2 (en) 2012-01-31
MY148776A (en) 2013-05-31
JP5134374B2 (ja) 2013-01-30
MX2007009243A (es) 2007-09-07
NO20073756L (no) 2007-08-29
WO2006082184A2 (en) 2006-08-10
EP1976563A2 (en) 2008-10-08
PE20060880A1 (es) 2006-09-23
US20080139459A1 (en) 2008-06-12
TW200638947A (en) 2006-11-16
RU2007132909A (ru) 2009-03-10
IL184565A0 (en) 2007-10-31
AU2006210230B2 (en) 2011-09-15
RU2443713C2 (ru) 2012-02-27
KR20070108535A (ko) 2007-11-12
UA96916C2 (ru) 2011-12-26
CA2594970A1 (en) 2006-08-10
BRPI0607248A2 (pt) 2010-10-19
CN101111268A (zh) 2008-01-23
TWI376234B (en) 2012-11-11
AU2006210230A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
AR052283A1 (es) Conjugados de un polipeptido y un pentasacarido que tienen propiedades farmacocineticas mejoradas y su uso en la fabricacion de medicamentos
BRPI0717505B8 (pt) conjugado de peptídeo e formulação farmacêutica
NL300903I2 (nl) Inotuzumab ozogamicin
PE20120514A1 (es) Fusiones y conjugados de agentes insulinotropicos o farmacos incretina con anticuerpos dab anti-albumina serica
ECSP088212A (es) Proceso para preparar conjugados de anticuerpo y maitansinoide
ZA201805336B (en) Amanitin conjugates
CU23850B1 (es) Composiciones farmacéuticas estabilizadas que comprenden fesoterodina
ATE524473T1 (de) Zytotoxische verbindungen
AR069747A1 (es) Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
BR122018071808B8 (pt) conjugado
WO2007047834A3 (en) Oral peptide conjugates for metabolic diseases
RU2015143057A (ru) Гипергликозилированные связывающие полипептиды
DK2283857T3 (da) Vaccinesammensætning omfattende konjugerede native N. Meningitidis kapselpolysaccharider
CR20120384A (es) Composición de farmaco conjugado
BRPI0417341A (pt) fator ix glicopeguilado
AR058433A1 (es) Derivado de 1,1-dioxido de 1,4-benzotiazepina ,procedimiento para su preparacion ,medicamentos que comprenden este compuesto y su uso
ATE520415T1 (de) Pneumokokken-polysaccharid-konjugat-vakzine
AR056137A1 (es) Un conjugado peptido inmunoglobulina y su uso como antiviral
ITMI20052036A1 (it) Composizioni farmaceutiche oftalmiche a base di amminoacidi e sodio ialuronato
CO6241131A2 (es) Vacuna
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
WO2004108747A3 (de) Lektin-konjugate
ATE388960T1 (de) Glykopeptidderivate mit carboxysacchariden
WO2007079404A3 (en) Drug-polymer conjugates
NO20090395L (no) Farmasoytiske preparater inneholdende monoklonale antidiotype anti-CA-125-antistoff og aluminiumderivater

Legal Events

Date Code Title Description
FA Abandonment or withdrawal